Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma.
about
Health-related quality of life in Hodgkin lymphoma: a systematic reviewAdvancement in high dose therapy and autologous stem cell rescue in lymphomaIsolated clonal cytogenetic abnormalities after high-dose therapy.Second malignancies in Hodgkin's disease: A review of the literature and report of a case with a secondary Lennert's lymphomaThe impact of treatment, socio-demographic and clinical characteristics on health-related quality of life among Hodgkin's and non-Hodgkin's lymphoma survivors: a systematic reviewCurrent status of autologous stem cell transplantation in relapsed and refractory Hodgkin's lymphomaSecond malignancies after autologous haematopoietic stem cell transplantation following modified BEAM conditioning regimen in patients with Hodgkin lymphoma - characteristics and risk factor analysis.Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience.Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma.Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group.Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma.Optimal treatment for relapsing patients with Hodgkin lymphoma.High-dose therapy followed by stem cell transplantation in Hodgkin's lymphoma: past and future.The GHSG Approach to Treating Hodgkin's Lymphoma.Accelerated Total Lymphoid Irradiation-containing Salvage Regimen for Patients With Refractory and Relapsed Hodgkin Lymphoma: 20 Years of Experience.Acute liver failure as the first manifestation of very late relapsing of Hodgkin's diseaseRisk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantationConditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway.Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma.High frequency of primary refractory disease and low progression-free survival rate of Hodgkin's lymphoma: a decade of experience in a Latin American center.Long-term outcomes after high dose therapy and autologous haematopoietic cell rescue for refractory/relapsed Hodgkin lymphoma.Quality of life of long-term survivors with Hodgkin lymphoma after high-dose chemotherapy, autologous stem cell transplantation, and conventional chemotherapy.Outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin lymphoma patients in a centre from Turkey.F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience
P2860
Q26740480-D2F47F6B-A89D-4F0A-85BD-E21506BB972EQ26795538-0120F6B1-E12F-436C-9F0C-00BFD5D8773DQ34108964-FA315790-5E84-4CDB-9C52-868CCEFAA752Q34412940-EFD921A5-006E-416F-AA93-762A7953AC65Q35148642-D3F856DB-ED47-415D-B3E4-C4959E5B9666Q35705317-464D905F-5B32-4839-B8DF-F59F8F922484Q36936841-ECB3E0F9-B289-4470-B3B0-15ECB348BA16Q37126593-18772FE1-991F-4E21-80D7-7C66692EE46AQ37216194-68471A50-A907-407A-BCA8-46B55534EABDQ37216339-B0E6564B-A46C-404D-B787-09119353EEEEQ37236041-AD467140-6848-49EA-AD57-1ADAF2C3A172Q37810094-6E73C88A-5B45-4487-A3BD-91B61C803E8DQ38132819-0DEC4A8D-B0BC-4215-8EC0-3D0B51F0480AQ38506223-2DAE1FB2-44A1-4AEC-A6AF-D516ECEBE83CQ39195424-E997C434-5E50-4D2C-9EB5-6268FDD60237Q39310377-FC4CC202-666A-4AF7-8AB2-A915CE410267Q40513698-B7DDD322-570A-4A14-AE88-49F34D31397AQ42847716-22B74E0B-E7A2-4B5E-8A00-387E4D357DCBQ45989594-426F03BF-A6BB-4B15-994E-A4AA0A3FB073Q46879226-21CB9299-D81E-4C61-9D9C-F6A65F5481EFQ48389559-350E9D6B-9524-4FC3-90E9-C6B6835357B9Q48786872-E8673B23-0FA4-487C-A22E-4818B0340BA2Q50873125-456013C6-0B32-431B-BEB0-3B9A78F7764BQ51748489-A6174232-3609-47BC-82A4-BE868AAFCC85Q58924291-3799AC1E-3771-40F3-A3DD-7C4C6B07B191
P2860
Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Long-term effects of high-dose ...... refractory Hodgkin's lymphoma.
@en
Long-term effects of high-dose ...... refractory Hodgkin's lymphoma.
@nl
type
label
Long-term effects of high-dose ...... refractory Hodgkin's lymphoma.
@en
Long-term effects of high-dose ...... refractory Hodgkin's lymphoma.
@nl
prefLabel
Long-term effects of high-dose ...... refractory Hodgkin's lymphoma.
@en
Long-term effects of high-dose ...... refractory Hodgkin's lymphoma.
@nl
P2093
P356
P1476
Long-term effects of high-dose ...... refractory Hodgkin's lymphoma.
@en
P2093
Craig H Moskowitz
Elyn Riedel
Joachim Yahalom
Karyn A Goodman
Subhash Gulati
Victoria Serrano
P304
P356
10.1200/JCO.2007.15.5507
P407
P577
2008-09-22T00:00:00Z